论文部分内容阅读
目的:观察α-干扰素(IFN-α)联合利巴韦林治疗慢性丙型肝炎的疗效及安全性。方法:69例慢性丙型肝炎随机分为治疗组(IFN-α与利巴韦林联合治疗)35例,与单用IFN-α组34例。结果:治疗3个月、6个月及1年随访时,治疗组HCV RNA阴转率为66.6%(22/33)、69.7%(23/33)和57.6%(19/33),明显优于对照组38.2%(13/34)、44.1%(15/34)与32.4% (11/34),P<0.05;治疗组的丙氨酸转氨酶(ALT)复常率高于IFN-α组,两组比较差异有统计学意义,P<0.05。两组均有不良反应,主要为发热、头痛、全身酸痛,白细胞、血小板和血红蛋白下降,除治疗组有2例因溶血性贫血而脱落,余均完成疗程,停药后不良反应均消失。结论:IFN-α联合利巴韦林治疗丙型肝炎优于单用IFN-α,疗效肯定、安全、可靠。
Objective: To observe the efficacy and safety of interferon-α (IFN-α) combined with ribavirin in the treatment of chronic hepatitis C Methods: A total of 69 patients with chronic hepatitis C were randomly divided into treatment group (IFN-α and ribavirin combination therapy) 35 cases, and IFN-α group alone 34 cases. Results: At 3 months, 6 months and 1 year follow-up, the HCV RNA negative rate in the treatment group was 66.6% (22/33), 69.7% (23/33) and 57.6% (19/33) (13/34), 44.1% (15/34) and 32.4% (11/34) in the control group, P <0.05. The alanine aminotransferase (ALT) recovery rate in the treatment group was higher than that in the IFN-α group , The difference between the two groups was statistically significant, P <0.05. Two groups had adverse reactions, mainly fever, headache, body aches, leukopenia, platelets and hemoglobin decreased, with the exception of the treatment group, 2 cases of hemolytic anemia and off, I completed the course of treatment, after stopping the adverse reactions were disappeared. Conclusion: IFN-α combined with ribavirin is superior to IFN-α alone in the treatment of hepatitis C, with definite, safe and reliable curative effect.